Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 19:2021:8862282.
doi: 10.1155/2021/8862282. eCollection 2021.

Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction

Kaiyi Mao  1 , Zongping Chen  1 , Mengzhi Li  1 , Chengren Gou  1 , Zidong Zhou  1 , Yong Yan  2 , Chao Chen  2 , Tong Liu  1 , Chenghong Zou  3 , Yuhong Yao  3 , Xu Li  3
Affiliations
Randomized Controlled Trial

Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction

Kaiyi Mao et al. Biomed Res Int. .

Abstract

Purpose: To evaluate the clinical efficacy of prodom in the administration of urokinase in the vagina in couples with impaired semen liquefaction.

Materials and methods: Overall, 261 patients with impaired semen liquefaction were randomly divided into prodom-assisted urokinase treatment (PAUT) group (n = 91), syringe-assisted urokinase treatment (SAUT) group (n = 86), and traditional treatment (TT) group (n = 84) in the first stage. If the first stage of treatment failed, other treatment methods were initiated instead and the patients were grouped according to the newer treatment method in the second stage. The pregnancy rate, time-to-conception, and treatment costs were evaluated in each group.

Results: In the first stage, the pregnancy rate in the PAUT, SAUT, and TT groups was 69.23%, 29.07%, and 22.62%, respectively; the time-to-conception was 2.66 ± 1.44, 3.69 ± 2.61, and 3.86 ± 3.00 months, respectively; the treatment costs were 658.18 ± 398.40, 666.67 ± 507.50, and 680.56 ± 480.94 $, respectively. The pregnancy rate and time-to-conception were different in the PAUT group compared with those in SAUT and TT groups (all P < 0.05). However, the difference in treatment costs was not significant (P = 0.717). In the second stage, 154 nonpregnant patients were divided into nine treatment groups, and the effects of changing TT to PAUT on the pregnancy rate, time-to-conception, and treatment costs were observed to be different from those of other treatments (all P < 0.05).

Conclusion: Prodom-assisted urokinase can effectively treat male infertility secondary to impaired semen liquefaction.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts to disclose.

Figures

Figure 1
Figure 1
Flow chart of the experimental design.
Figure 2
Figure 2
Packing sample product label of prodom-assisted urokinase.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th edn. Geneva: World Health Organization; 2010.
    1. Eisenberg M. L., Lathi R. B., Baker V. L., Westphal L. M., Milki A. A., Nangia A. K. Frequency of the male infertility evaluation: data from the National Survey of Family Growth. Journal of Urology. 2013;189(3):1030–1034. doi: 10.1016/j.juro.2012.08.239. - DOI - PubMed
    1. Schaeffer A. J., Hotaling J. M. Claims-based analysis of male infertility: a cautious step in the right direction. Fertility and Sterility. 2016;105(3):599–600. doi: 10.1016/j.fertnstert.2015.11.044. - DOI - PubMed
    1. Xiong G.-B., Yao W.-L., Wu F.-H. Shenfu Qiangjing decoction improves non-inflammatory and non-liquefied semen in kidney-yang deficiency men. Zhonghua Nan Ke Xue. 2009;15(12):1138–1141. - PubMed
    1. Check J. H. Treatment of male infertility. Clinical and Experimental Obstetrics & Gynecology. 2007;34(4):201–206. - PubMed

Publication types

Substances

LinkOut - more resources